Susceptibility to vaginal yeast in most used antifungal in Maringá, Paraná, Brazil;Susceptibilidad de levaduras vaginales a los antif úngicos más utilizados en Maringá, Paraná, Brasil

Acta Bioquimica Clinica Latinoamericana

Volumn 42, Issue 4, 2008, Pages 561-566

  Dota, Kelen Fátima Dalben ^a   Shinobu, Cristiane Suemi ^a   Patussi, Eliana Valéria ^a,b   Consdaro, Marcia Edilaine Lopes ^a,b   Svidzinski, Terezinha Inez Estivalet ^a,b  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

^b Universidade Estadual de Maringá ^*  (Brazil)

Author keywords

Antifungal; In vitro resistance; Treatment; Vulvovaginal candidiasis

Indexed keywords

CANDIDA ALBICANS;

EID: 70249105348     PISSN: 03252957     EISSN: 03252957     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Sobel JD. Vulvovaginitis due to Candida glabrata: an emerging problem. Mycoses 1998; 41 Suppl 2: 18-22.
2. Bustamante Cl. Treatment of Candida infection: a view from the trenches. Curr Opin Infect Dis 2005; 18 (6): 490-495
3. Corsello S, Spinillo A, Osnengo G, Penna C, Guaschino S, Beltrame A, et al. An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol 2003; 110: 66-72.
4. Ziarrusta GB. vulvovaginitis candidiásica. Rev lberoam Micol 2002; 19: 22-24
5. 5. Saporiti AM, Gómez SL, Galeano M, Davel G, Vovot W, Rodero L. Candidiasis vaginal: etiología y perfil de sensibilidad a agentes antifúngicos de uso clínico. Rev Argent Microbiol 2001; 33: 217-222 (Pubitemid 34230012)
6. Alvares CA, Svidzinski TIE, Consolara MEL. Candidíase vulvovaginal: fatores predisponentes do hospedeiro e virulência das leveduras. J Bras Patol Med Lab 2007; 43 (5): 319-327
7. Consolara MEL, Albertoni TA, Svidzinski AE, Peralta RM, Svidzinski TIE. Vulvovaginal candidiasis is associated with the production of germ tubes by Candida albicans. Mycopatology 2005; 159: 501-507
8. Dan M, Poch F, Levin D. High rate of vaginal infections caused by non-C. albicans Candida species among asymptomatic women. Med Mycol 2002; 40: 383-386
9. Ferraza MHSH, Maluf MLF, Consolara MEL, Shinobu CS, Svidzinski TIE, Batista MR. Caracterização de leveduras isoladas da vagina e sua associação com candidíase vulvovaginal em duas cidades do sul do Brasil. RGBO 2005; 27 (2): 58-63.
10. Consolara MEL, Albertoni TA, Yoshida CS, Mazucheli J, Peralta RM, Svidzinski TIE. Correlation of Candida species and symptoms among patients with vulvovaginal candidiasis in Maringá, Paraná, Brazil. Rev lberoam Micol 2004; 21: 202-205
11. a ed. Rio de Janeiro: GuanabaraKoogan, 2000.
12. Pichová I, Pavlickova L, Dostal J, Dolejsi E, HruskovaHeidingsfeldova O, Weber J, et al. Secreted aspartic proteinases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaneae. inhibition with peptidomimetic inhibitors. Eur J Biochem 2001; 268: 2669-2677
13. Sobel JD. Candidal vulvovaginitis. Clin Obstet Gynecol 1993; 36: 153-165
14. Martins MD, Lozano-Chiu M, Rex JH. Point prevalence of oropharyngeal carriage of f luconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 1997; 25: 843-846
15. 15. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistent candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173: 219-225 (Pubitemid 26006822)
16. Rosenberg MJ, Waugh MS, Bumhill MS. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Farm Plann Perspect 1998; 30: 89-92.
17. 17. Sugita T, Kurosaka S, Yajitate M, Sato H, Nishikawa A. Extracellular proteinase and phospholipase activity of three genotypic strains of a human pathogenic yeast, Candida albicans. Microbiol Immunol 2002; 46: 881-883 (Pubitemid 36019163)
18. Clinical Laboratory Standards Institute. 2002. Reference method for broth dilution antifungal susceptibility testing for yeasts. Approved standard M27-A2, 2nd ed. Clinical Laboratory Standards Institute. Wayne, Pa.
19. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005; 43: 2155-2162
20. Galle LC, Gianinni MJSM. Prevalência e susceptibilidade de leveduras vaginais. J Bras Patol Med Lab 2004; 40 (4): 229-236
21. 21. Ozean SK, Budak F, Yucesoy G, Susever S, Willke A. Prevalence, susceptibility profile and proteinase production of yeasts causing vulvovaginitis in Turkish women. J Compilation 2006; 114: 139-145 (Pubitemid 43356925)
22. Ventolini G, Baggish MS, Walsh PM A. Vulvovaginal candidiasis from non-albicans species: retrospective study of recurrence rate after fluconazole therapy. J Reprod Med 2006; 51 (6): 475-478